# data[].attributes.body
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity

Domenica Rubino, MD; Niclas Abrahamsson, MD; Melanie Davies, MD

# data[].attributes.body
GLP1 semaglutide administration vs Placebo

# data[].attributes.body
The dependent variable is affected by the independent variable (Kim et al., 2021). In this case, it is weight loss.

# data[].attributes.body
What effect does continued treatment with 2.4 mg of subcutaneous semaglutide have on the maintenance of body weight loss in adults with overweight or obesity without diabetes?

# data[].attributes.body
-Efficacy end points were analyzed using the full analysis set

-Assessments of adverse events and laboratory parameters used the safety analysis set

-All results from statistical analyses were accompanied by 2-sided 95% confidence intervals and corresponding P values

-Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc).

-Continuous end points were analyzed using analysis of covariance, with randomized treatment as a factor and baseline (week 20) end point value as a covariate.

-Categorical end points were analyzed using logistic regression, with the same factor and covariate (baseline body weight in kilograms was used for the analysis of participants who gained weight) (Rubino et al., 2021)

# data[].attributes.body
The trial tested two groups of obese individuals and gave both groups a set period of semaglutide injections. After reaching the therapeutic dose, the second group was switched to the placebo injection.

Among adults with overweight or obesity who completed a 20-week run-in period with subcutaneous semaglutide, 2.4 mg once weekly, maintaining treatment with semaglutide compared with switching to placebo resulted in continued weight loss over the following 48 weeks (Rubino et al., 2021). Those who switched to placebo ultimately gained the weight back.

# data[].attributes.attachment_link.title
Effect of Weekly Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity

# data[].attributes.attachment_link.description
This randomized trial compares the effects of continuing weekly treatment with subcutaneous semaglutide vs switching to placebo on change in body weight over 48 weeks among adults with overweight or obesity who completed a 20-week run-in period with semaglutide.

# data[].attributes.body
Kim, M., Mallory, C., & Valerio, T., (2022). Statistics for Evidence-Based Practice in Nursing, (3rd Edition). Jones & Bartlett Learning

Rubino, D., Albrahamsson, N., & Davies, M. (2021, March 23). Effect of weekly Semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA Network | Home of JAMA and the Specialty Journals of the American Medical Association. https://jamanetwork.com/journals/jama/article-abstract/2777886